1. Raspaldo H. Volumizing effect of a new hyaluronic acid sub-dermal facial filler: A retrospective analysis based on 102 cases. Journal of Cosmetic and Laser Therapy 2008;10(3):134-42.
2. Alijotas-Reig J, Garcia-Gimenez V. Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature. J Eur Acad Dermatol Venereol 2008;22(2):150-161.
3.Edwards PC, Fantasia JE. Review of long-term adverse effects associated with the use of chemically-modified animal and nonanimal source hyaluronic acid dermal fillers. Clin Interv Aging 2007;2(4):509-519.
4. Ghislanzoni M, Bianchi F, Barbareschi M, Alessi E. Cutaneous granulomatous reaction to injectable hyaluronic acid gel. Br J Dermatol 2006;154(4):755-758.
5. Hönig JF, Brink U, Korabiowska M. Severe granulomatous allergic tissue reaction after hyaluronic acid injection in the treatment of facial lines and its surgical correction. J Craniofac Surg 2003;14(2):197-200.
6. Nicolau PJ. Long-lasting and permanent fillers: biomaterial influence over host tissue response. Plast Reconstr Surg 2007;119(7):2271-2286.
7. Okada S, Okuyama R, Tagami H, Aiba S. Eosinophilic granulomatous reaction after intradermal injection of hyaluronic acid. Acta Derm Venereol 2008;88(1):69-70.
8. Pons-Guiraud A. Adverse reactions to injectable fillers. Ann Dermatol Venereol 2008;135(Suppl 1):S171-S174.
9. Zielke H, Wölber L, Wiest L, Rzany B. Risk profiles of different injectable fillers: results from the Injectable Filler Safety Study (IFS Study). Dermatol Surg 2008;34(3):326-335.
10. Andre P, Lowe NJ, Parc A, Clerici TH, Zimmermann U. Adverse reactions to dermal fillers: a review of European experiences. J Cosmet Laser Ther 2005;7(3-4):171-176.
11. Apikian M, Roberts S, Goodman GJ. Adverse reactions to polylactic acid injections in the periorbital area. J Cosmet Dermatol 2007;6(2):95-101.
12. Beljaards RC, de Roos KP, Bruins FG. NewFill for skin augmentation: a new filler or failure? Dermatol Surg 2005;31(7 Pt 1):772-776.
13. Bodokh I, Simonet P. Polylactic acid injections (Newfill) in the treatment of facial lipodystrophy in HIV-positive patients. Ann Dermatol Venereol 2006;133(5 Pt 1):429-432.
14. Borelli C, Kunte C, Weisenseel P, Thoma-Greber E, Korting HC, Konz B. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physio 2005;18(6):273-278.
15. Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005;52(2):233-239.
16. Christensen L, Breiting V, Janssen M, Vuust J, Hogdall E. Adverse reactions to injectable soft tissue permanent fillers. Aesthetic Plast Surg 2005;29(1):34-48.
17. Dijkema SJ, van der Lei B, Kibbelaar RE. New-fill injections may induce late-onset foreign body granulomatous reaction. Plast Reconstr Surg 2005;115(5):76e-78e.
18. Dionyssopoulos A, Nikolis A, Patsatsi A, Sotiriadis D. Granulomas of the lips: a rare complication after injection of polylactic acid for aesthetic augmentation. J Plast Reconstr Aesthet Surg 2007;60(9):1079-1080.
19. Goldan O, Garbov-Nardini G, Regev E, Orenstein A, Winkler E. Late-onset infections and granuloma formation after facial polylactic acid (New-Fill) injections in women who are heavy smokers. Plast Reconstr Surg 2008;121(5):336e-338e.
20. Hamilton DG, Gauthier N, Robertson BF. Late-onset, recurrent facial nodules associated with injection of poly-L-lactic acid. Dermatol Surg 2008;34(1):123-126.
21. Hodzic-Avdagic N, Stege H, Hilton S, Sarbia M, Ruzicka T, Bruch-Gerharz D. Granuloma development after wrinkle injection with polylactate. Hautarzt 2005;56(4):372-374.
22. Kavouni A, Catalan J, Brown S, Mandalia S, Barton SE. The face of HIV and AIDS: can we erase the stigma? AIDS Care 2008;20(4):485-487.
23. Keni SP, Sidle DM. Sculptra (injectable poly-L-lactic acid). Facial Plast Surg Clin North Am 2007;15(1):91-97.
24. Lam SM, Azizzadeh B, Graivier M. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plast Reconstr Surg 2006;118(Suppl 3):55S-63S.
25. Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg 2003;27(5):354-366.
26. Lombardi T, Samson J, Plantier F, Husson C, Küffer R. Orofacial granulomas after injection of cosmetic fillers. Histopathologic and clinical study of 11 cases. J Oral Pathol Med 2004;33(2):115-120.
27. Lowe NJ, Maxwell CA, Patnaik R. Adverse reactions to dermal fillers: review. Dermatol Surg 2005;31(11 Pt 2):1616-1625.
28. Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 2006;7(3):181-185.
29. Nairns S. Minimizing adverse events associated with poly-L-lactic acid injection. Dermatol Surg 2008;34(Supp, 1):S100-S104.
30. Oppel T SM, Flaig M, Korting HC. Facial foreign body granulomas after dermal injection of a polylactate-based implant for wrinkles. J Dtsch Dermatol Ges 2003;1(3):220-222.
31. Parada MB, Michalany NS, Hassun KM, Bagatin E, Talarico S. A histologic study of adverse effects of different cosmetic skin fillers. Skin Med 2005;4(6):345-349.
32. Poveda R, Bagán JV, Murillo J, Jiménez Y. Granulomatous facial reaction to injected cosmetic fillers--a presentation of five cases. Med Oral Patol Oral Cir Bucal 2006;11(1):E1-E5.
33. Rongioletti F. Granulomatous reactions from aesthetic dermal micro-implants. Ann Dermatol Venereol 2008;135(1 Pt 2):S59-S65.
34. Stewart DB, Morganroth GS, Mooney MA, Cohen J, Levin PS, Gladstone HB. Management of visible granulomas following periorbital injection of poly-L-lactic Acid. Ophthal Plast Reconstr Surg 2007;23(4):298-301.
35. Vochelle D. The use of poly-L-lactic acid in the management of soft-tissue augmentation: a five-year experience. Semin Cutan Med Surg 2004;23(4):223-226.
36. Wildemore JK, Jones DH. Persistent granulomatous inflammatory response induced by injectable poly-L-lactic acid for HIV lipoatrophy. Dermatol Surg 2006;32(11):1407-1409.
37. Wolfram D, Tzankov A, Piza-Katzer H. Surgery for foreign body reactions due to injectable fillers. Dermatology 2006;213(4):300-304.
38. Zimmermann US, Clerici TJ. The histological aspects of fillers complications. Semin Cutan Med Surg 2004;23(4):241-250.
39. Alam M, Levy R, Pajvani U, Ramierez JA, Guitart J, Veen H, et al. Safety of radiofrequency treatment over human skin previously injected with medium-term injectable soft-tissue augmentation materials: a controlled pilot trial. Lasers Surg Med 2006;38(3):205-210.
40. Alam M, Yoo SS. Technique for calcium hydroxylapatite injection for correction of nasolabial fold depressions. J Am Acad Dermatol 2007;56(2):285-289.
41. Beer KR. Radiesse nodule of the lips from a distant injection site: report of a case and consideration of etiology and management. J Drugs Dermatol 2007;6(8):846-847.
42. Godin MS, Majmundar MV, Chrzanowski DS, Dodson KM. Use of radiesse in combination with restylane for facial augmentation. Arch Facial Plast Surg 2006;8(2):92-97.
43. Jacovella PF, Peiretti CB, Cunille D, Salzamendi M, Schechtel SA. Long-lasting results with hydroxylapatite (Radiesse) facial filler. Plast Reconstr Surg 226;118(Suppl 3):15S-21S.
44. Jansen DA, Graivier MH. Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg 2006;118(Suppl 3):22S-30S.
45. Sadick NS, Katz BE, Roy D. A multicenter, 47-month study of safety and efficacy of calcium hydroxylapatite for soft tissue augmentation of nasolabial folds and other areas of the face. Dermatol Surg 2007;33(Suppl 2):S122-126.
46. Sankar V, McGuff HS. Foreign body reaction to calcium hydroxylapatite after lip augmentation. J Am Dent Assoc 2007 138(8):1093-1096.
47. Tzikas TL. Evaluation of the Radiance FN soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg 2004;6(4):234-239.
48. Tzikas TL. A 52-month summary of results using calcium hydroxylapatite for facial soft tissue augmentation. Dermatol Surg 2008;34(Suppl 1):S9-S15.
49. Bechara FG, Gambichler T, Brockmeyer NH, Sand M, Altmeyer P, Hoffmann K. Hyaluronic Acid New Formulation: Experience in HIV-Associated Facial Lipoatrophy. Dermatology 2008;217(3):244-249.
50. De Boulle K. Management of complications after implantation of fillers. J Cosmet Dermatol 2004;3(1):2-15.
51. Gladstone HB, Cohen JL. Adverse effects when injecting facial fillers. Semin Cutan Med Surg 2007;26(1):34-39.
52. Moyle GJ, Lysakova L, Brown S, Sibtain N, Healy J, Priest C, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004;5(2):82-87.
53. Busso M, Applebaum D. Hand augmentation with Radiesse (Calcium hydroxylapatite). Dermatol Ther 2007;20(6):385-387.
54. Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg 2006;118(Suppl 3):34S-45S.
55. Sklar JA, White SM. Radiance FN: a new soft tissue filler. Dermatol Surg 2004;30(5):764-768.
56. Smith S, Busso M, McClaren M, Bass LS. A randomized, bilateral, prospective comparison of calcium hydroxylapatite microspheres versus human-based collagen for the correction of nasolabial folds. Dermatol Surg 2007;33(Suppl 2):S112-S121.
57. Klaus Hoffmann M, and the Juvéderm™ VOLUMA™ Study Investigators Group,. Volumizing Effects of a Smooth, Highly Cohesive, Volumizing 20-mg/mL Hyaluronic Acid Filler: Prospective European Study: Department of Dermatology, Ruhr University, Bochum, Germany, 2008.
58. Lemperle G, Morhenn VB, Pestonjamasp V, Gallo RL. Migration studies and histology of injectable microspheres of different sizes in mice. Plast Reconstr Surg 2004;113(5):1380-1390.
59. Carruthers A, Liebeskind M, Carruthers J, Forster BB. Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds. Dermatol Surg 2008;34(Suppl 1):S78-S84.
60. Comite SL, Liu JF, Balasubramanian S, Christian MA. Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse). Dermatol Online J 2004;10(2):2-9.
61. Juvéderm® HYDRATE On-line Distance Learning Program. EU/0043/2010. Referred to as “Distance Learning Slide Deck” Or “Juvederm HYDRATE DLP_UK 02”
62. Juvéderm® HYDRATE Brand Positioning Deck. Referred to as “Juvéderm Hydrate Brand Positioning 160210v3”
63. Juvéderm® HYDRATE Media Backgrounder.
64. Juvéderm® HYDRATE PI/Safety Info. Referred to as Juv HYDRATE notice 020708
65. Taieb M. Hyaluronic Acid plus Mannitol Treatment for Improved Skin Hydration and Elasticity. Poster vorgestellt auf der AMWC, Monaco, April 2010
